Encompass Health
EHC
$122.53
+0.67%
Encompass Health Corporation is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized post-acute rehabilitative care to patients recovering from strokes, neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations through a nationwide network of inpatient rehabilitation facilities. As the clear scale leader in the fragmented inpatient rehabilitation segment, Encompass Health operates as a pure-play post-acute provider following the 2022 spin-off of its home health and hospice business (now Enhabit), giving investors direct exposure to the demographic-driven growth of rehabilitation services. The current investor narrative centers on the company's ability to sustain mid-single-digit to low-double-digit revenue growth through capacity expansion — new hospital openings and bed additions — while expanding margins via operating leverage on its fixed-cost hospital base, a thesis reinforced by the most recent quarter's 9.0% year-over-year revenue growth and 25.7% EBITDA margin. Attention is also focused on the durability of Medicare and managed care reimbursement under a stable regulatory backdrop, the company's consistent dividend declarations, and its ongoing share repurchase program, all of which support the case for Encompass as a defensive, cash-generative healthcare compounder trading at a modest valuation relative to its growth profile.…
EHC
Encompass Health
$122.53
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating: Buy. The core thesis is that Encompass Health is a defensive, cash-generative healthcare compounder executing a clear growth strategy — 9.0% revenue growth, expanding margins, and new hospital openings — while trading at a discounted 18.9x trailing PE and a 0.78 PEG, with 12 analysts carrying an average target of $148.17 that implies 21.7% upside. The consensus is uniformly bullish with no Sell or Hold ratings visible, and the tight $140-$155 target range signals high conviction in the trajectory.
Supporting evidence: revenue grew 9.0% year-over-year to $1.587 billion in Q1 2026, accelerating from 7-8% growth in 2024; EBITDA margin expanded to 25.7% from 24.0% a year earlier and 22.2% in Q4 2024; trailing twelve-month free cash flow is $464.4 million, comfortably covering capex, dividends, and buybacks; and ROE of 23.2% and ROA of 9.8% are strong for a capital-intensive provider. The PEG ratio of 0.78 is below 1.0, and the PE of 18.9x sits at the low end of its three-year historical band of roughly 12x-25x, suggesting the market is pricing in conservative expectations relative to the company's growth and margin trajectory.
Risks and conditions: the biggest risks are Medicare reimbursement policy (65% of payer mix), the leveraged balance sheet (D/E of 1.11), and the stock's recent momentum stall near the 52-week high of $127.99. This Buy would downgrade to Hold if revenue growth decelerates below 7% or if EBITDA margin falls below 24%, and would upgrade to a stronger conviction if the stock breaks above $127.99 on volume or if PE re-rates toward the sector's mid-20s multiple. Relative to its own history and sector peers, the stock appears undervalued — the discount to the healthcare sector's typical PE and the low PEG suggest a valuation re-rating opportunity if execution continues.
Sign up to view all
EHC 12-Month Price Forecast
Encompass Health presents a compelling risk-reward setup: a defensive, low-beta (0.608) healthcare compounder growing revenue at 9.0% with expanding margins, trading at a discounted 18.9x PE and a sub-1.0 PEG, and covered by 12 uniformly bullish analysts with 21.7% average upside. The primary concern is the stock's negative 1-year return of -4.0% and 20.2-point underperformance versus SPY, which suggests the market has been slow to reward execution, and the recent 1-month pullback of 2.5% near the 52-week high of $127.99 indicates momentum has stalled. The base case (50% probability) targets $140-$148, assuming 8-9% revenue growth and stable margins, while the bull case (30%) targets $148-$155 on a valuation re-rating and the bear case (20%) targets $92.77-$115 on reimbursement or margin deterioration. I would upgrade to high confidence if the stock breaks above $127.99 on volume or if Q2 2026 earnings show revenue growth above 9% with EBITDA margin above 26%; I would downgrade to neutral if revenue growth decelerates below 7% or if Medicare reimbursement policy turns adverse.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $148.17 and implied upside of +20.9% versus the current price.
Average Target
$148.17
0 analysts
Implied Upside
+20.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $155
Analyst target range
Twelve analysts cover Encompass Health, and the consensus is uniformly bullish. The average target price is $148.17, implying approximately 21.7% upside from the current price of $121.71. The recommendation field shows "none" in the data, but the institutional ratings history is overwhelmingly positive: Barclays has maintained Overweight through multiple updates (most recently May 2026), UBS reiterated Buy in October 2025, KeyBanc maintained Overweight in September 2025, and BofA Securities, Truist Securities, and Stephens & Co. all carry Buy or Overweight ratings. There are no Sell or Hold ratings visible in the institutional data, indicating strong conviction among covering analysts.
The target range spans $140.00 to $155.00, a relatively tight $15 spread (roughly 10% of the midpoint) that signals high analyst conviction and low uncertainty about the company's trajectory. The high target of $155.00 implies about 27.4% upside and likely assumes continued mid-to-high single-digit revenue growth, further margin expansion from operating leverage, successful new hospital openings, and possibly a valuation re-rating toward the sector average. The low target of $140.00 still implies 15.0% upside and appears to price in more conservative assumptions around reimbursement pressure or slower capacity growth, but notably even the most cautious analyst sees meaningful appreciation. The consensus EPS estimate of $9.26 (range $9.20-$9.32) and revenue estimate of $8.99 billion (range $8.94-$9.03 billion) are tightly clustered, reinforcing the picture of a well-understood, predictable business. The combination of a 21.7% average upside, a tight target range, and a complete absence of bearish ratings makes Encompass Health one of the more compelling risk-reward setups in the healthcare facilities space, though investors should note that the stock's 20.2-point underperformance versus SPY over the past year suggests the market has been slow to reward this consensus view.
Bulls vs Bears: EHC Investment Factors
The bull case currently has stronger evidence: revenue growth is accelerating to 9.0%, EBITDA margins are expanding to 25.7%, the PEG ratio of 0.78 signals undervaluation, and all 12 covering analysts carry bullish ratings with 21.7% average upside. The bear case rests primarily on structural Medicare concentration (65% of payer mix), a leveraged balance sheet (D/E of 1.11), and a stock that remains down 4.0% over the past year despite a powerful recent rally. The single most important tension is whether the market will re-rate a company that is executing well but trades at a discount to sector peers — if the PE remains stuck near 18.9x despite 9% growth and expanding margins, the stock could stay range-bound; if it re-rates toward the sector's mid-20s multiple, the upside to the $148 average target becomes achievable. The recent 1-month pullback of 2.5% near the 52-week high of $127.99 is the key near-term test: a breakout would confirm the recovery, while a failure could retest the $110-$115 support zone.
Bullish
- Revenue growth accelerating to 9.0% YoY: Q1 2026 revenue of $1.587 billion rose 9.0% year-over-year from $1.455 billion, accelerating from roughly 7-8% growth in 2024. The sequential staircase from $1.302 billion in Q2 2024 to $1.587 billion in Q1 2026 demonstrates consistent, demographically driven volume expansion.
- EBITDA margin expanding to 25.7%: Q1 2026 EBITDA margin reached 25.7% ($407.8 million), up from 24.0% a year earlier and 22.2% in Q4 2024. This 350-basis-point expansion over five quarters reflects operating leverage on a fixed-cost hospital base as incremental volume flows through at high contribution margins.
- Undervalued on PEG and historical PE: The PEG ratio of 0.78 is below 1.0, and the trailing PE of 18.9x sits at the low end of its three-year historical band of roughly 12x-25x. The forward PE of 18.2x represents a meaningful discount to the S&P 500 and the healthcare sector's typical mid-20s multiple.
- 21.7% upside to analyst consensus: Twelve analysts carry an average target price of $148.17, implying 21.7% upside from $121.71, with a tight $140-$155 range signaling high conviction. No Sell or Hold ratings are visible, and the consensus EPS estimate of $9.26 is tightly clustered ($9.20-$9.32).
Bearish
- Medicare concentration at 65% of payer mix: Medicare accounts for $1.039 billion, or roughly 65%, of the disclosed payer mix, making government reimbursement policy the single most important swing factor for the growth outlook. Any adverse rate update or regulatory change would directly pressure revenue and margins.
- Negative 1-year return despite rally: The stock is down 4.0% over the past year and has lagged SPY by 20.2 percentage points, even after a 19.9% three-month rally. This divergence suggests the market has been slow to reward the consensus view and that overhead supply from late-2025 sellers may cap upside.
- Leveraged balance sheet with 1.11 D/E: Debt-to-equity of 1.11 and quarterly interest expense of $31.8 million reflect a capital-intensive, leveraged operator. While interest coverage of roughly 9.5x is comfortable, rising rates or reimbursement tightening would strain the capital structure and limit buyback capacity.
- Momentum stalling near 52-week high: The 1-month change is -2.5% versus +19.9% over three months, and the stock sits at roughly 82% of its 52-week range with resistance at $127.99 just 5.2% above. The maximum drawdown of -26.2% over the past year shows the stock can experience meaningful peak-to-trough declines despite its 0.608 beta.
EHC Technical Analysis
Encompass Health is in a sustained recovery uptrend that has only recently begun to stall. The stock is up 19.9% over the past three months and 21.3% over six months, yet the 1-year change is -4.0%, meaning the trailing twelve-month return remains negative despite the powerful recent rally. At $121.71, the stock sits at roughly 82% of its 52-week range (52-week low of $92.77, high of $127.99), positioning it in the upper quartile of its annual band — a zone that reflects momentum but also leaves limited headroom before overhead resistance. The divergence between the strong 3-month/6-month gains and the negative 1-year return tells the story of a stock that sold off hard in late 2025 and has spent 2026 climbing back toward its prior highs.
Short-term momentum has decelerated sharply even as the intermediate trend remains constructive. The 1-month change is -2.5%, a stark contrast to the +19.9% 3-month and +21.3% 6-month gains, indicating the rally has paused or entered a consolidation phase near the highs. Relative strength versus the S&P 500 confirms this bifurcation: EHC has outperformed SPY by 16.9 percentage points over three months and 5.9 points over six months, but has lagged by 1.4 points over the past month and a striking 20.2 points over the past year. The stock's beta of 0.608 signals it is roughly 40% less volatile than the broader market, so this month-long pullback is modest in absolute terms and consistent with a low-beta name digesting a large advance rather than a trend reversal.
Key technical levels are well defined by the 52-week range. Immediate resistance sits at the 52-week high of $127.99, roughly 5.2% above the current $121.71 price; a decisive breakout above that level would confirm the recovery as a new leg higher and likely draw momentum buyers. Support is anchored at the 52-week low of $92.77, about 23.8% below current levels, with intermediate support likely forming in the $110-$115 zone where the stock consolidated in July and early August before its early-August gap higher. The maximum drawdown of -26.2% over the past year underscores that despite the low beta, this stock can experience meaningful peak-to-trough declines, making position sizing and stop discipline important for holders.
Beta
0.61
0.61x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
-2.8%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | -0.9% | -2.0% |
| 3m | +22.7% | +1.4% |
| 6m | +22.9% | +15.0% |
| 1y | -2.8% | +15.7% |
| ytd | +15.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Encompass Health's revenue trajectory is steadily growing, with the most recent quarter (Q1 2026, ended 2026-03-31) delivering $1.587 billion in revenue, up 9.0% year-over-year from $1.455 billion in Q1 2025. The multi-quarter trend shows consistent sequential and annual expansion: revenue rose from $1.302 billion in Q2 2024 to $1.351 billion in Q3 2024, $1.405 billion in Q4 2024, $1.455 billion in Q1 2025, $1.458 billion in Q2 2025, $1.478 billion in Q3 2025, $1.544 billion in Q4 2025, and $1.587 billion in Q1 2026 — a clear upward staircase with YoY growth accelerating from roughly 7-8% in 2024 to 9.0% in the latest quarter. Revenue is heavily concentrated in Medicare at $1.039 billion (roughly 65% of the disclosed payer mix), followed by managed care at $167.7 million, Medicaid at $46.1 million, workers' compensation at $8.1 million, and patients at $7.1 million, meaning government reimbursement policy is the single most important swing factor for the growth outlook. The steady, demographically driven volume growth — supported by an aging population requiring post-acute rehabilitation — underpins a durable investment case, though the Medicare concentration introduces policy risk.
Profitability is robust and improving. Q1 2026 net income was $194.5 million on $1.587 billion of revenue, a 12.3% net margin, up from $151.5 million (10.4% margin) in Q1 2025 and $120.9 million (8.6% margin) in Q4 2024. EBITDA reached $407.8 million in Q1 2026, a 25.7% EBITDA margin, versus $349.6 million (24.0%) in Q1 2025 and $312.4 million (22.2%) in Q4 2024 — a clear expansion trend. Operating income of $301.6 million produced a 19.0% operating margin, up from 18.3% a year earlier, while the company-level operating margin of 17.7% and net margin of 9.5% reflect the capital-intensive, fixed-cost nature of hospital operations where incremental volume flows through at high contribution margins. The reported gross margin of 95.7% (company-level) versus the quarterly gross margin of 48.4% reflects differing cost classifications, but the directional signal is unambiguous: margins are expanding as revenue scales.
Balance sheet and cash flow metrics indicate a financially healthy but leveraged operator. Debt-to-equity stands at 1.11, with a current ratio of 1.08 and a quick ratio of 1.08, indicating adequate but not abundant short-term liquidity. Free cash flow on a trailing twelve-month basis is $464.4 million, and Q1 2026 free cash flow was $150.7 million after $162.4 million of capital expenditures, reflecting the heavy ongoing capex required to build and expand hospitals. Operating cash flow of $313.1 million in Q1 2026 comfortably covered capex, dividends ($20.3 million), and buybacks ($71.6 million), demonstrating the business generates sufficient internal cash to fund growth while returning capital. ROE of 23.2% and ROA of 9.8% are strong for a capital-intensive healthcare provider, and the interest coverage ratio of roughly 9.5x provides a solid cushion on the debt load, though the 1.11 debt-to-equity ratio and $31.8 million quarterly interest expense warrant monitoring if rates rise or reimbursement tightens.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+9.0%
YoY Comparison
Gross Margin
48.4%
Latest Quarter
Free Cash Flow
$464399999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Because Encompass Health is solidly profitable — Q1 2026 net income of $194.5 million and positive trailing earnings — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 18.9x and a forward PE of 18.2x, a narrow gap that implies the market expects only modest earnings growth over the next twelve months, consistent with the analyst consensus EPS estimate of $9.26 versus the current run-rate. The PEG ratio of 0.78 — below 1.0 — suggests the stock is undervalued relative to its growth rate, a notable signal for a defensive healthcare name. The EV/EBITDA of 9.5x and EV/Sales of 2.5x provide corroborating context, placing the company at a reasonable multiple for a stable, cash-generative hospital operator.
Relative to the broader healthcare sector, Encompass trades at a discount on most metrics. The trailing PE of 18.9x compares favorably to the healthcare sector's typical mid-20s multiple, and the forward PE of 18.2x represents a meaningful discount to the S&P 500's forward multiple. The PS ratio of 1.80x and PB ratio of 4.37x reflect the capital-intensive, asset-heavy nature of the hospital business, where book value is less informative than earnings power. The EV/EBITDA of 9.5x is in line with or slightly below comparable acute-care and post-acute hospital operators, suggesting the market is not pricing in a premium despite Encompass's leadership position in inpatient rehabilitation. The discount appears unjustified given the company's 9.0% revenue growth, expanding margins, and 23.2% ROE, implying a potential valuation re-rating opportunity if execution continues.
Historically, Encompass's valuation has compressed meaningfully. The PE ratio has fallen from 25.2x in Q3 2025 and 21.7x in Q2 2025 to 18.9x currently, while the PS ratio has declined from 8.6x in Q3 2025 to 1.80x now (though the PS series reflects a change in revenue classification). The PB ratio of 4.37x is near the middle of its historical range of roughly 2.2x to 5.4x over the past several years. The current PE of 18.9x sits at the lower end of the stock's historical band, which spanned roughly 12x to 25x over the past three years, suggesting the market is pricing in conservative expectations. This combination of a low PEG, a below-sector PE, and a PE near the bottom of its own historical range points to a value opportunity rather than fundamental deterioration, provided the company sustains its growth and margin trajectory.
PE
18.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's leveraged, capital-intensive model and its dependence on continued volume growth to justify valuation. Debt-to-equity stands at 1.11 with $31.8 million of quarterly interest expense, and while interest coverage of roughly 9.5x is comfortable, the balance sheet leaves limited room for error if reimbursement tightens. Capital expenditures of $162.4 million in Q1 2026 consumed over half of the $313.1 million in operating cash flow, meaning free cash flow of $464.4 million on a trailing basis is structurally constrained by the need to build and expand hospitals. Revenue concentration is the most acute operational risk: Medicare accounts for $1.039 billion, or roughly 65% of the disclosed payer mix, so a single adverse reimbursement update from CMS could pressure both revenue and the 25.7% EBITDA margin. Additionally, the business must sustain mid-single-digit to low-double-digit growth to justify its valuation, and any deceleration below 7% would likely trigger multiple compression given the stock's negative 1-year return of -4.0%.
Market and competitive risks stem from valuation sensitivity, sector rotation, and the stock's recent momentum stall. At a trailing PE of 18.9x and forward PE of 18.2x, Encompass trades at a discount to the healthcare sector's mid-20s multiple, but the narrow gap between trailing and forward PE implies the market expects only modest earnings growth, leaving little cushion if estimates disappoint. The stock's beta of 0.608 means it is roughly 40% less volatile than the market, which is a defensive attribute but also means it may lag in strong risk-on rotations; indeed, it has underperformed SPY by 20.2 percentage points over the past year. The 1-month change of -2.5% versus +19.9% over three months signals that short-term momentum has decelerated sharply near the 52-week high of $127.99, and a failure to break through that resistance could invite profit-taking. Competitive disruption from alternative post-acute settings, such as skilled nursing facilities or home-based rehabilitation, could pressure patient volumes, though Encompass's scale leadership in inpatient rehabilitation provides a meaningful moat.
Worst-case scenario: a combination of adverse Medicare reimbursement changes, slower-than-expected new hospital openings, and margin compression would compress both earnings and the multiple. If the PE reverted to the low end of its historical band near 12x-13x on forward EPS of $9.26, the stock could trade down toward the $110-$115 range, and a more severe scenario involving reimbursement cuts could push it toward the 52-week low of $92.77, representing roughly 23.8% downside from the current $121.71. The analyst low target of $140.00 still implies 15.0% upside, so even the most cautious covering analyst does not model a decline, but the stock's maximum drawdown of -26.2% over the past year demonstrates that such declines are possible. In a realistic adverse scenario, an investor could lose 20-25% from current levels, with the $92.77 52-week low serving as the downside anchor.
FAQ
The most severe risk is Medicare reimbursement policy: Medicare accounts for $1.039 billion, or roughly 65% of the payer mix, so any adverse CMS rate update would directly pressure revenue and the 25.7% EBITDA margin. Second is financial leverage — debt-to-equity of 1.11 with $31.8 million of quarterly interest expense leaves limited flexibility if rates rise or cash flow slows, and capital expenditures of $162.4 million in Q1 2026 consumed over half of operating cash flow. Third is valuation and momentum risk: the stock is down 4.0% over the past year and has lagged SPY by 20.2 percentage points, and the recent 1-month decline of 2.5% near the 52-week high of $127.99 suggests the rally may be stalling. Fourth is competitive and operational risk — slower new hospital openings or volume shifts to alternative post-acute settings could decelerate growth below the 7-8% level needed to justify the valuation.
The 12-month forecast has three scenarios: a base case (50% probability) targeting $140-$148, assuming 8-9% revenue growth and stable 25-26% EBITDA margins, aligned with the analyst average target of $148.17; a bull case (30% probability) targeting $148-$155, assuming a valuation re-rating toward the sector's mid-20s PE and revenue growth above 9%; and a bear case (20% probability) targeting $92.77-$115, assuming adverse Medicare reimbursement changes or margin compression below 24%. The base case is most likely, with the key assumption being that Medicare reimbursement remains stable and the company executes its capacity expansion plan. The tight analyst target range of $140-$155 and the absence of Sell or Hold ratings reinforce the view that the risk is skewed to the upside, though the stock's negative 1-year return shows the market has yet to fully embrace this consensus.
EHC appears undervalued on both absolute and relative bases. The trailing PE of 18.9x and forward PE of 18.2x are below the healthcare sector's typical mid-20s multiple and represent a meaningful discount to the S&P 500's forward multiple, while the PEG ratio of 0.78 is below 1.0, signaling the stock is cheap relative to its growth rate. The PE has compressed from 25.2x in Q3 2025 to 18.9x now, placing it at the low end of its three-year historical band of roughly 12x-25x, and the EV/EBITDA of 9.5x is in line with or slightly below comparable hospital operators. The market appears to be pricing in conservative expectations — only modest earnings growth, given the narrow gap between trailing and forward PE — despite 9.0% revenue growth and expanding margins. If the company sustains its trajectory, a re-rating toward the sector average would imply meaningful upside toward the $148 analyst target.
From a risk/reward perspective, EHC offers 21.7% upside to the analyst average target of $148.17 against roughly 23.8% downside to the 52-week low of $92.77, a favorable skew for a low-beta (0.608) defensive healthcare name. The company is executing well — 9.0% revenue growth, 25.7% EBITDA margin, 23.2% ROE — while trading at a discounted 18.9x PE and a 0.78 PEG, and all 12 covering analysts carry bullish ratings. The biggest downside risk is Medicare reimbursement policy, since Medicare is 65% of the payer mix, and the stock's negative 1-year return of -4.0% shows the market has been slow to reward execution. It is a good buy for patient investors with a 12-24 month horizon who can tolerate a 20-25% drawdown in an adverse reimbursement scenario, but less suitable for short-term traders given the recent 2.5% one-month pullback and stalled momentum near the 52-week high.
EHC is better suited for long-term investment than short-term trading. The company is a mature, capital-intensive hospital operator with a beta of 0.608, meaning it is roughly 40% less volatile than the market, and its growth is driven by slow, demographic-based volume expansion rather than rapid cyclical swings. The dividend yield of 0.67% with a low payout ratio of 12.6% and the ongoing buyback program support a total-return profile that rewards patience, while the negative 1-year return of -4.0% and 20.2-point underperformance versus SPY illustrate that short-term momentum can be unrewarding. Earnings visibility is high — the consensus EPS estimate of $9.26 is tightly clustered between $9.20 and $9.32 — which reduces event risk but also limits the potential for sharp short-term moves. A minimum holding period of 12-24 months is appropriate to capture the capacity expansion cycle and any valuation re-rating toward the $148 analyst target.